RemeGen Secures Fast-Track Designation for RC88 in Platinum-Resistant Ovarian Cancer
China-based biotech RemeGen Co., Ltd (HKG: 9995; SHA: 688331) has received fast-track designation (FTD) from...
RemeGen
RemeGen’s Telitacicept Secures FDA Approval for Global Phase III Study in Primary Sjogren’s Syndrome
RemeGen (HKG: 9995), a China-based pharmaceutical company, has received approval from the US Food and...
RemeGen Ltd Receives FDA Clearance for MSLN-Targeting ADC RC88 in Gynecological Tumors
China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has announced that it has received clinical clearance...
Akeso Biopharma’s Cadonilimab Meets Primary Endpoint in Phase III Cervical Cancer Study
China-based Akeso Biopharma (HKG: 9926) has announced that its Phase III AK104-303 study for cadonilimab...
RemeGen’s Telitacicept Receives Full Approval for Systemic Lupus Erythematosus in China
China-based pharmaceutical company RemeGen (HKG: 9995) has announced the conversion of conditional approval to complete...
RemeGen and Akeso Biopharma Initiate Phase II Study for Gastric Cancer Combo Therapy
China-based RemeGen Ltd (HKG: 9995) is poised to conduct a Phase II clinical study in...
RemeGen’s Telitacicept Shows Positive Phase III Results in Rheumatoid Arthritis Study
China-based RemeGen Co., Ltd (HKG: 9995, SHA: 688331) has announced positive results from the China...
RemeGen Ltd Reports 20.56% YOY Revenue Growth in H1 2023 Financial Results
China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has released its financial report for the first...
RemeGen’s Novel Bispecific Antibody RC148 Receives Clinical Trial Approval
China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has announced that it has received clinical trial...
Innovent Biologics and RemeGen Partner on Clinical Study for PD-1 Inhibitor and ADC Drugs
China-based Innovent Biologics Inc., (HKG: 1801) has entered into a clinical study and supply cooperation...
RemeGen Ltd Receives Approval for Phase I Clinical Study of RC198 in Solid Tumors
RemeGen Ltd (HKG: 9995) has announced that it has received approval from the Human Research...
RemeGen Ltd Partners with Shandong Cancer Hospital for ADC Development and Integrated System
RemeGen Ltd (HKG: 9995) has announced a strategic partnership with Shandong Cancer Hospital to establish...
RemeGen’s Disitamab Vedotin (RC48) Clears for Phase I Study in HER2-Positive Tumors
RemeGen Ltd (HKG: 9995), a biopharmaceutical company, has announced that it has received approval from...
RemeGen’s RC48 Receives Two Clinical Trial Approvals for Breast Cancer Treatments
RemeGen Ltd (HKG: 9995) has announced the receipt of two clinical trial approvals for its...
RemeGen Gains NMPA Approval for Phase I/IIa Study of RC88 with Junshi Bio’s PD-1 Inhibitor
China-based pharmaceutical firm RemeGen (HKG: 9995) has received approval from the National Medical Products Administration...
RemeGen Gains NMPA Approval for RC48 and Pyrotinib Clinical Study
China-based RemeGen Ltd (HKG: 9995) has announced receiving the go-ahead from the National Medical Products...
RemeGen and Allist Partner to Assess ADC and EGFR Inhibitor Combination in NSCLC
China-based RemeGen Ltd (HKG: 9995) and Allist Pharmaceuticals Inc. (SHA: 688578) have announced a clinical...
RemeGen’s RC48 Gains NMPA Approval for Phase II Study in Bladder Cancer
China – based biopharmaceutical company RemeGen Ltd (HKG: 9995) has announced that it has received...
RemeGen’s RC108 Receives FDA Go-Ahead for Phase I Clinical Study
China-based biopharma RemeGen Ltd (HKG: 9995) has announced receiving approval from the US FDA to...
RemeGen’s RC118 Receives Orphan Drug Designations for Gastric and Pancreatic Cancers
China-based RemeGen Ltd announced that its antibody drug conjugate (ADC) drug candidate RC118 has obtained...